On its way to acquisition by Bristol-Myers Squibb (BMS), Celgene continues to pursue its own cancer-focused collaborations, with a pair of biotechs announcing the partnerships today. Celgene has secured exclusive options to two Kyn Therapeutics clinical programs under the companies’ global strategic collaboration to develop novel immuno-oncology therapies. The biotech giant agreed to license Kyn’s […]